PDGFRB and neoplasm: Sorafenib, an FDA-approved multi-kinase inhibitor for HCC, exerts its anti-tumor effects by inhibiting cell proliferation and angiogenesis through targeting the VEGFR, PDGFR, and RAF/MEK/ERK pathways [38].